Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	30.44	142.04	157.08	0.18	-7.79
Depreciation & Amortization	0.02	0.02	0.02	0.01	0.01
Loss (Gain) From Sale of Investments	3.3	-3.59	1.53	0.7	-
Stock-Based Compensation	3.67	1.23	2.93	1.99	0.84
Other Operating Activities	-8.03	10.44	0.14	0.18	-0.4
Change in Accounts Receivable	154.59	-157.11	-13.11	0.19	-2.51
Change in Accounts Payable	-0.49	-0.48	-	0.34	-0.11
Change in Income Taxes	-48.91	-3.83	36.35	-	-
Change in Other Net Operating Assets	-9.17	-	-	-	-
Operating Cash Flow	125.42	-11.27	184.93	3.6	-9.97
Operating Cash Flow Growth	-	-	5038.23%	-	-
Capital Expenditures	-0.04	-0.01	-0.04	-0.02	-0.01
Investment in Securities	-87.97	4.14	-211.45	-	-
Investing Cash Flow	-88.01	4.13	-211.49	-0.02	-0.01
Issuance of Common Stock	6.39	1.66	3.64	-	23.28
Repurchase of Common Stock	-39.57	-10.43	-	-	-
Other Financing Activities	-0.04	-0.01	-0.02	-0	-1.11
Financing Cash Flow	-33.22	-8.78	3.62	-0	22.18
Foreign Exchange Rate Adjustments	-3.12	1.97	-0.15	-0.18	0.4
Net Cash Flow	1.07	-13.94	-23.09	3.4	12.6
Free Cash Flow	125.39	-11.28	184.89	3.58	-9.98
Free Cash Flow Growth	-	-	5064.39%	-	-
Free Cash Flow Margin	193.95%	-5.20%	79.71%	23.22%	-312.17%
Free Cash Flow Per Share	0.96	-0.09	1.41	0.03	-0.08
Cash Income Tax Paid	54.15	37.22	-0.88	-1.39	-2.52
Levered Free Cash Flow	116.98	-42.25	152.97	2.59	-6.76
Unlevered Free Cash Flow	116.98	-42.25	152.97	2.59	-6.76
Change in Working Capital	96.02	-161.42	23.24	0.53	-2.62

Source: S&P Global Market Intelligence. Standard template. Financial Sources.